Appendix Table C83Comparative harms: combination oral selective antihistamine plus oral decongestant versus oral selective antihistamine

Author, YearTreatment GroupNSedationHeadachePalpitationsInsomniaAnxietyOther: Chest Pain
Bronsky, 1995Loratadine 10 mg/Pseudoephedrine 240 mg221/21262555
Loratadine 10 mg217/21242311
Chervinsky, 2005aDesloratadine 5 mg/Pseudoephedrine 240 mg214/200810
Desloratadine 5 mg214/20082
Pseudoephedrine 240 mg222/204611
Grosclaude, 1997Cetirizine 10 mg/Pseudoephedrine 240 mg230/2306.14.300
Cetirizine 10 mg231/2313.
Grubbe, 2009Desloratadine 5 mg/Pseudoephedrine 240 mgbc2006.59.5
Desloratadine 5 mgde1987.13.0
Pleskow, 2005Desloratadine 5 mg/Pseudoephedrine 240 mg37265152
Desloratadine 5 mg37246111
Schenkel, 2002fDesloratadine 5 mg/Pseudoephedrine 240 mg336/336334.82.70.3g
Desloratadine 5 mg340/3402.
Sussman, 1999hFexofenadrine 120 mg/Pseudoephedrine 240 mg215/21507.301.80
Fexofenadrine 120 mg218/2181.412.42.812.81.4

N/n = Number of patients randomized/number of patients analyzed.

Symptom severity is unspecified unless otherwise noted (MILD, MOD = moderate, or SEV = severe).


Unclear if proportions of patients, or reports.


Other: Increased heart rate 3.9 BPM.


No serious or unexpected adverse events reported; 7 patients discontinued due to adverse events.


Other: no increased heart rate reported.


No serious or unexpected adverse events reported; 9 patients discontinued due to adverse events.


Number of reports.


Assigned Severe category by abstractor.


Number of reports.

From: Appendix C, Evidence Tables

Cover of Treatments for Seasonal Allergic Rhinitis
Treatments for Seasonal Allergic Rhinitis [Internet].
Comparative Effectiveness Reviews, No. 120.
Glacy J, Putnam K, Godfrey S, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.